As global incidences of respiratory disorders increase, the drive to develop and make available innovative therapeutic options is also increasing. To achieve this aim, and provide our clients with relevant, robust in vivo efficacy models, Axis Bio has validated the models shown in the table below. We offer intranasal and intratracheal routes of administration (or use of a nebuliser).
The type of analysis performed varies from model to model, but we can offer the following:
Axis Bio performs the bleomycin induced pulmonary fibrosis model and offers design flexibility to ensure alignment with our clients’ requirements. We run an acute, ‘target engagement’ model through to a more in depth, longer duration study.Read more ►
Acute lung damage
Axis Bio offers the HCl induced model.
Axis Bio has a range of induction options: